Enterome to Present Three Abstracts on its Novel OncoMimics™ Cancer Immunotherapies at ASCO 2022
Paris, France – May 27, 2022: Enterome, a clinical stage
biopharmaceutical company developing first-in-class immunomodulatory
drugs based on its bacterial Mimicry drug discovery platform, today
announced the publication of three abstracts related to its OncoMimcs™
pipeline, including EO2401, its first-in-class off-the-shelf OncoMimics™
cancer immunotherapy, ahead of poster presentations at the American
Society of Clinical Oncology (ASCO) Annual Meeting, taking place June
3-7, 2022 in Chicago and virtually.
More info >> |